It has also been shown that MSI/dMMR PDACs may have significant intra-tumor heterogeneity and may lead to the development of metastatic MSS PDACs and recurrent beta-2-microglobulin (B2M) gene inactivation, which may be associated with tumor resistance to immune checkpoint inhibitor therapy [100]. The gene discussed is B2M; the disease is neoplasm.